In one study, seventy-five percent of the patients demonstrated a positive response following the active phase of TMS compared to 17 percent in the sham phase.
In the US, rTMS for schizophrenia is considered off-label, the FDA has approved it in major depressive disorder only, probably because the results in other disorders are mixed.